Is Divis Laboratories a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Divis Laboratories Ltd is a good quality company .

Is Divis Laboratories undervalued or overvalued?

The key valuation ratios of Divis Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Divis Laboratories share price return in the past 10 years?

Divis Laboratories Ltd share price has appreciated 21.4% annually (CAGR) over the past ten years.

Is Divis Laboratories a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Divis Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Divis Laboratories?

The latest standalone P/E ratio of Divis Laboratories as of 22-Nov-2024 is 86.70.

What is the P/B ratio of Divis Laboratories?

The latest standalone P/B ratio of Divis Laboratories as of 22-Nov-2024 is 11.68.

What is the 52-week high and low of Divis Laboratories?

The 52-week high of Divis Laboratories is Rs. 6276.20 and the 52-week low is Rs. 3350.05.

Divis Laboratories Ltd - Stock Valuation and Financial Performance

Name: Divis Laboratories
Brand: Divis Laboratories

BSE: 532488 | NSE: DIVISLAB | Pharmaceuticals & Drugs | Large Cap

Place order

Divis Lab Share Price

₹5,999.40 23.70 0.40%
as on 22-Nov'24 16:59

10 Year X-Ray of Divis Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	33.1%	35.6%	28.8%	21.7%	28.5%	25.4%	32.1%	35.1%	19.4%	16.5%	-
Value Creation Index ⓘ	1.5	2.2	1.6	0.9	1.5	1.3	1.9	2.1	0.7	0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	3,115	3,776	4,064	3,891	4,946	5,394	6,969	8,960	7,767	7,845	8,614
Sales YoY Gr.	-	21.2%	7.6%	-4.3%	27.1%	9.1%	29.2%	28.6%	-13.3%	1%	-
Adj EPS ⓘ	32.2	41.5	41	32.5	50.2	49.4	75	110.5	65.3	59.6	69.2
YoY Gr.	-	28.9%	-1.4%	-20.7%	54.5%	-1.5%	51.8%	47.4%	-40.9%	-8.8%	-
BVPS (₹) ⓘ	131.7	161.7	201.8	223.2	262.1	275.4	350.2	441.8	481.8	512.1	516.7
Adj Net Profit ⓘ	855	1,102	1,087	862	1,331	1,311	1,990	2,933	1,734	1,582	1,836
Cash Flow from Ops. ⓘ	826	1,038	1,150	776	954	1,216	1,947	1,912	2,459	1,261	-
Debt/CF from Ops. ⓘ	0	0	0	0.1	0.1	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	10.8%	9.7%	4%	1%
Adj EPS ⓘ	7.1%	3.5%	-7.4%	-8.8%
BVPSⓘ	16.3%	14.3%	13.5%	6.3%
Share Price	21.4%	27.7%	7.8%	59.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	26.5	28.3	22.5	15.3	20.7	18.4	24	27.9	14.2	12	13.4
Op. Profit Mgn % ⓘ	37.7	37.7	36.6	32.6	37.9	33.9	41.2	43.3	30.5	28.2	29.7
Net Profit Mgn % ⓘ	27.5	29.2	26.7	22.2	26.9	24.3	28.6	32.7	22.3	20.2	21.3
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	297	245	268	371	307	294	247	239	293	277	184
Cash Conv. Cycle ⓘ	173	156	144	154	142	153	126	130	182	183	160

Recent Performance Summary

Sales growth is good in last 4 quarters at 17.06%

Return on Equity has declined versus last 3 years average to 13.40%

Sales growth has been subdued in last 3 years 4.02%

Net Profit has been subdued in last 3 years -7.36%

Latest Financials - Divis Laboratories Ltd.

	Standalone	Consolidated
TTM EPS (₹)	69.2	69.2
TTM Sales (₹ Cr.)	8,432	8,614
BVPS (₹.) ⓘ	513.6	516.7
Reserves (₹ Cr.) ⓘ	13,582	13,664
P/BV ⓘ	11.68	11.61
PE ⓘ	86.70	86.75

From the Market
52 Week Low / High (₹)	3350.05 / 6276.20
All Time Low / High (₹)	7.70 / 6276.20
Market Cap (₹ Cr.)	1,59,265
Equity (₹ Cr.)	53.1
Face Value (₹)	2
Industry PE ⓘ	43.4

Management X-Ray of Divis Lab:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Divis Lab

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Divis Lab

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	3,115	3,776	4,064	3,891	4,946	5,394	6,969	8,960	7,767	7,845
Operating Expenses ⓘ	1,949	2,358	2,617	2,629	3,073	3,571	4,108	5,079	5,398	5,639
Manufacturing Costs	318	350	368	411	462	540	617	758	897	902
Material Costs	1,213	1,505	1,534	1,534	1,825	2,109	2,324	2,967	3,053	3,129
Employee Cost	290	361	500	456	542	621	826	946	975	1,094
Other Costs ⓘ	127	142	215	227	244	302	342	407	473	514
Operating Profit ⓘ	1,166	1,418	1,447	1,263	1,873	1,823	2,861	3,881	2,369	2,206
Operating Profit Margin (%)	37.4%	37.6%	35.6%	32.4%	37.9%	33.8%	41.1%	43.3%	30.5%	28.1%
Other Income ⓘ	45	97	75	113	156	190	63	116	345	339
Interest ⓘ	3	5	3	2	5	7	2	2	2	4
Depreciation ⓘ	136	118	123	142	169	186	256	312	343	378
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	1,072	1,393	1,395	1,231	1,855	1,819	2,666	3,684	2,369	2,163
Tax ⓘ	221	267	335	354	502	443	682	723	545	563
Profit After Tax	852	1,126	1,060	877	1,353	1,377	1,984	2,960	1,824	1,600
PAT Margin (%)	27.3%	29.8%	26.1%	22.5%	27.3%	25.5%	28.5%	33.0%	23.5%	20.4%
Adjusted EPS (₹)	32.1	42.4	40.0	33.0	51.0	51.9	74.8	111.5	68.8	60.4
Dividend Payout Ratio (%)	31%	24%	25%	30%	31%	31%	27%	27%	44%	50%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	3,495	4,293	5,357	5,925	6,957	7,310	9,295	11,728	12,767	13,571
Share Capital ⓘ	27	53	53	53	53	53	53	53	53	53
Reserves ⓘ	3,469	4,240	5,304	5,872	6,904	7,257	9,242	11,675	12,714	13,518
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	26	42	36	63	106	34	0	0	0	0
Long Term Debt	1	0	0	0	0	0	0	0	0	0
Short Term Debt	25	41	36	63	106	34	0	0	0	0
Trade Payables	227	233	446	411	492	591	763	796	762	824
Others Liabilities ⓘ	1,364	330	1,590	1,948	1,240	1,491	1,329	2,095	1,334	1,542
Total Liabilities ⓘ	5,112	4,898	7,429	8,347	8,795	9,425	11,387	14,619	14,863	15,937
Fixed Assets
Gross Block	1,953	2,196	1,794	2,373	2,634	3,514	4,692	5,624	6,365	6,760
Accumulated Depreciation	644	757	235	377	546	732	988	1,299	1,643	2,021
Net Fixed Assetsⓘ	1,309	1,439	1,559	1,996	2,088	2,782	3,704	4,325	4,722	4,739
CWIP ⓘ	218	264	444	120	492	920	711	470	212	778
Investmentsⓘ	733	803	1,631	1,889	1,946	971	0	72	77	82
Inventories	1,163	1,208	1,320	1,351	1,772	1,864	2,145	2,829	3,000	3,184
Trade Receivables	742	881	901	1,014	1,163	1,413	1,677	2,424	1,793	2,156
Cash Equivalents ⓘ	65	73	79	112	115	123	2,156	2,819	4,214	3,980
Others Assetsⓘ	883	230	1,496	1,864	1,219	1,352	995	1,681	845	1,018
Total Assets ⓘ	5,112	4,898	7,429	8,347	8,795	9,425	11,387	14,619	14,863	15,937

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	826	1,038	1,150	776	954	1,216	1,947	1,912	2,459	1,261
PBT ⓘ	1,072	1,393	1,395	1,231	1,855	1,819	2,666	3,684	2,369	2,163
Adjustment ⓘ	91	61	94	32	84	60	189	240	144	81
Changes in Working Capital ⓘ	-126	-155	-37	-219	-500	-218	-264	-1370	419	-607
Tax Paid ⓘ	-211	-261	-302	-269	-484	-445	-644	-641	-473	-376
Cash Flow From Investing Activity ⓘ	-521	-406	-1,140	-478	-685	-83	75	-2,195	-2,707	-269
Capex	-307	-396	-377	-274	-733	-1,183	-910	-713	-473	-1,003
Net Investments	-253	-67	-831	-285	-43	1,056	928	-1,549	-2,439	434
Others ⓘ	39	56	68	81	91	43	57	67	205	300
Cash Flow From Financing Activityⓘ	-303	-631	2	-314	-246	-1,091	-35	-532	-797	-799
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-1	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-1	-2	-2	-1	-4	-6	-1	0	0	-2
Dividend Paid ⓘ	-265	-531	0	-319	-265	-850	0	-531	-796	-796
Others ⓘ	-36	-98	5	6	23	-236	-34	-1	-1	-1
Net Cash Flow ⓘ	3	0	13	-17	23	41	1,987	-816	-1,045	193

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	26.37	28.91	21.98	15.55	21	19.3	23.9	28.16	14.89	12.15
ROCE (%)	33.06	35.57	28.75	21.68	28.5	25.36	32.07	35.06	19.36	16.46
Asset Turnover Ratio	0.67	0.76	0.67	0.5	0.58	0.6	0.67	0.69	0.53	0.51
PAT to CFO Conversion(x)	0.97	0.92	1.08	0.88	0.71	0.88	0.98	0.65	1.35	0.79
Working Capital Days
Receivable Days	85	78	79	89	80	86	81	83	98	91
Inventory Days	122	114	112	125	114	122	105	101	136	143
Payable Days	57	56	81	102	90	94	106	96	93	93

Divis Laboratories Ltd Stock News

Divis Laboratories Ltd FAQs

What is the share price of Divis Lab?

Company share prices are keep on changing according to the market conditions. The closing price of Divis Lab on 22-Nov-2024 16:59 is ₹5,999.4.

What is the market cap of Divis Lab?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Nov-2024 16:59 the market cap of Divis Lab stood at ₹1,59,265.2.

What is the P/E ratio of Divis Lab?

The latest P/E ratio of Divis Lab as of 22-Nov-2024 16:59 is 86.70.

What is the P/B ratio of Divis Lab?

The latest P/B ratio of Divis Lab as of 22-Nov-2024 16:59 is 11.68.

What is the 52-week high and low of Divis Lab?

The 52-week high of Divis Lab is ₹6,276.2 and the 52-week low is ₹3,350.1.

What is the TTM revenue of Divis Lab?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Divis Lab is ₹8,432 ( Cr.) .

About Divis Laboratories Ltd

Divi’s Laboratories Limited is a Company limited by shares, incorporated and domiciled in India. The Company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. The Company is a public limited company and the Company’s equity shares are listed in BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) in India.

Business area of the company

The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.

Business Segments

Generic APIs
Custom Synthesis
Nutraceuticals

Products

Capecitabine
Carbidopa
Diltiazem HCl
Dextromethorphan Base
Dextromethorphan HBr
Fosphenytoin Sodium
Gabapentin
Iopamidol
Irbesartan
Levetiracetam
Levodopa
Mesalamine
Nabumetone
Naproxen
Naproxen Sodium
Niacin
Olmesartan Medoxomil
Phenylephrine HCl
Pregabalin
Proguanil HCl
Quetiapine Fumarate
Tamsulosin HCl
Telmisartan
Triprolidine HCl
Valacyclovir HCl
Valsartan
Venlafaxine HCl
Vigabatrin

Awards

2001:

Occupational Health and Safety Management System (OHSAS-18001)

2002:

May Day Award for Best Management

2003:

Shreshtha Suraksha Puraskar
Appreciation certificate for Meritorious performance in implementing the programmes of ‘Safe Guarding the Environment and Pollution Control’
Viswakarma Rashtriya Puraskar

2004:

Good Practice in Cleaner Production and Pollution Control

2005:

National Award for Excellence Water Management 2005
Appreciation certificate for Meritorious performance in implementing the programmes of ‘Safe Guarding the Environment and Pollution Control & Plantation work’.
May Day Award for Best Management

2006:

National Award for Excellence Water Management and Certificate for Water efficient unit.
National Award for Excellence Water Management and Certificate for Water efficient unit - Beyond the fence.
Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’.

2007:

Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’.

2008:

Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’ on the Occasion of the World Environment
Finalist Certificate

2009:

Certified and Awarded for ‘Best Green Belt Development’
Occupational Health and Safety Management System (OHSAS-18001:2007)
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’

2011:

Best Green Belt Development.

2012:

India Business Leader Award ‘First Generation Entrepreneur of the Year’
Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’.

2013:

ISO 14064 - 1: 2006 Green House Gas Accounting verification.
May Day award for Best Management

2014:

Winner of ‘Special Commendation’ for Golden Peacock Award for Corporate Social Responsibility

2015:

Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
May Day award for Best Management
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’.

2018:

Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
ISO 14001 : 2018 (Re- certification) ‘Environmental Management System’.
May Day award for Best Management

Milestones

1990: Inception of Divi’s as Divi’s Research Centre(DRC)
1995: Setup First Manufacturing facility(Unit-1) near Hyderabad
2000: First USFDA Inspection
2002: Commenced New Manufacturing Facility (Unit 2) near Vishakhapatnam
2003: Divi’s Labs listed on Indian Stock Exchange
2007: Set up Nutraceuticals facility at Unit 2
2008: First MFDS(Korea) inspection
2010: Established New Research Centre at Hyderabad
2011: First EU GMP and Japan PMDA Inspection
2012: First TGA Inspection
2013: First Slovenian Medicines Agency inspection for Unit-II
2014: Divi’s reaches a milestone of 8700 employees
2014: First COFEPRIS inspection
2015: New corporate office inaugurated at Hyderabad
2015: New Pilot block with 160 Reactors and Kilo Lab
2016: First Anvisa (Brazil) inspection
2017: Divi’s reaches a milestone of 11,000 employees and becomes one of the largest employers in the combined state of Telangana/Andhra Pradesh
2017: Reaches the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad
2018: Market capital of $5B Reached
2018: 10 new production blocks commissioned
2018: Expanded the product portfolio to over 30 products
2019: Setting up Manufacturing plant at Kakinada
2019: Additional investment of $250M towards expansion of production blocks in Unit -I and Unit- II